Transitional cell carcinoma
Not yet recruitingSafety and efficacy study of nadofaragene firadenovec administered to the renal pelvis in adults with low-grade upper tract urothelial carcinoma
Safety and efficacy study of nadofaragene firadenovec administered to the renal pelvis in adults with low-grade upper tract urothelial carcinoma
- Disease:Transitional cell carcinoma
- Substances:Nadofaragene firadenovec
France- Participants:18–64 years · 65+ years
- Substances:Nadofaragene firadenovec
- Sponsor:Ferring Pharmaceuticals A/S








